KRAS and invasive ductal breast carcinoma: If KRAS-mutant MCPs share other common molecular signatures with typical ductal adenocarcinomas, such as TP53 mutation and copy number losses of cyclin-dependent kinase inhibitor (CDKN) 2A and SMAD4 [5, 6], characteristic histology in these cases may depend on inflammatory events unrelated to genetic background.